Avelumab in unresectable/metastatic, progressive, grade 2–3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials
David Chan, Víctor Rodríguez-Freixinós, Mark Doherty, K. Wasson, N. Iscoe, William Raskin, Julie Hallet, Sten Myrehaug, Calvin Law, Alia Thawer, Khang Nguyen, Simron Singh
Topics & Concepts
MedicineClinical endpointAvelumabNeuroendocrine tumorsInternal medicineGastroenterologyProgressive diseaseOncologySurgeryClinical trialChemotherapyImmunotherapyCancerPembrolizumabNeuroendocrine Tumor Research AdvancesLung Cancer Research StudiesThyroid Cancer Diagnosis and Treatment